VRTX
VERTEX PHARMACEUTICALS INC / MA
- Latest sale
- $548k
- Nov 16 · Routine
- Form 4 sales
- 1,509
- On record
- Form 144 notices
- 47
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleRoutineJun 15 2026
Sold 4,062 shares at $450.00 ($1.8M)
Bozic Carmen, EVP and CMO
10b5-1 planSold 19.3% of holdings ($9.5M position)16,953 shares left1.8x usual sizeFiling
- 2 Form 4 saleRoutineJun 18 +3 days
Sold 1,020 shares at $462.17 ($471k)
Bozic Carmen, EVP and CMO
10b5-1 planSold 6% of holdings ($7.8M position)15,933 shares left0.4x usual sizeFiling
- 3 Form 4 saleRoutineJun 26 +8 days
Sold 596 shares at $482.50 ($288k)
Bozic Carmen, EVP and CMO
10b5-1 planSold 3.7% of holdings ($7.7M position)15,337 shares left0.3x usual sizeFiling
- 4 Form 4 saleRoutineJul 1 +5 days
Sold 828 shares at $502.71 ($416k)
Liu Joy, EVP and Chief Legal Officer
10b5-1 planSold 4.1% of holdings ($10M position)19,131 shares left0.9x usual sizeFiling
- 5 Form 4 saleRoutineJul 2 +1 day
Sold 1,541 shares at $519.00 ($800k)
McKechnie Duncan, EVP, Chief Commercial Officer
10b5-1 planSold 12.3% of holdings ($6.5M position)11,001 shares left0.6x usual sizeFiling
- 6 Form 4 saleRoutineJul 2 same day
Sold 1,500 shares at $524.99 ($787k)
Tatsis Ourania, EVP, Chief Reg. & Quality Off.
10b5-1 planSold 3.2% of holdings ($24.6M position)45,321 shares left2x usual sizeFiling
- 7 Form 4 saleRoutineNov 16 +137 days
Sold 271 shares at $547.86 ($148k)
Bhatia Sangeeta N., Director
10b5-1 planSold 5.5% of holdings ($2.7M position)4,653 shares left0.9x usual sizeFiling
- 8 Form 4 saleRoutineNov 16 same day
Sold 1,000 shares at $547.86 ($548k)
Thornberry Nancy, Director
10b5-1 planSold 47.4% of holdings ($1.2M position)1,109 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (newest 400 of 1,556)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 | Thornberry Nancy | Director | Form 4 sale | 1,000 | $548k | 47.4% | Routine | SEC |
| Nov 16, 2026 | Bhatia Sangeeta N. | Director | Form 4 sale | 271 | $148k | 5.5% | Routine | SEC |
| Jul 2, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 1,500 | $787k | 3.2% | Routine | SEC |
| Jul 2, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Form 4 sale | 1,541 | $800k | 12.3% | Routine | SEC |
| Jul 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Form 4 sale | 828 | $416k | 4.1% | Routine | SEC |
| Jun 26, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 596 | $288k | 3.7% | Routine | SEC |
| Jun 18, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 1,020 | $471k | 6.0% | Routine | SEC |
| Jun 15, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 4,062 | $1.8M | 19.3% | Routine | SEC |
| Jun 5, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 1,745 | $785k | 7.7% | Routine | SEC |
| Jun 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Form 4 sale | 828 | $364k | 4.0% | Routine | SEC |
| May 29, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 1,974 | $888k | 8.0% | Routine | SEC |
| May 15, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Form 4 sale | 33 | $15k | 0.5% | Routine | SEC |
| May 15, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 1,354 | $614k | 5.2% | Routine | SEC |
| May 12, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 6,988 | $3.1M | 21.1% | Unusual | SEC |
| May 4, 2026 | Bhatia Sangeeta N. | Director | Form 4 sale | 318 | $135k | 6.1% | Routine | SEC |
| May 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Form 4 sale | 1,104 | $469k | 5.1% | Routine | SEC |
| Apr 1, 2026 | Liu Joy | EVP and Chief Legal Officer | Form 4 sale | 978 | $439k | 4.3% | Routine | SEC |
| Mar 27, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,329 | $1.1M | 6.6% | Routine | SEC |
| Mar 13, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,329 | $1.1M | 6.2% | Routine | SEC |
| Mar 11, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Form 4 sale | 2,633 | $1.3M | 17.4% | Routine | SEC |
| Mar 4, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Form 4 sale | 2,437 | $1.2M | 13.9% | Routine | SEC |
| Mar 2, 2026 | Liu Joy | EVP and Chief Legal Officer | Form 4 sale | 892 | $442k | 3.8% | Routine | SEC |
| Feb 27, 2026 | Kewalramani Reshma | CEO & President | Form 4 sale | 40,000 | $19.7M | 28.9% | Routine | SEC |
| Feb 27, 2026 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,329 | $1.1M | 5.8% | Routine | SEC |
| Feb 26, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 357 | $173k | 5.1% | Routine | SEC |
| Feb 25, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 260 | $126k | 0.6% | Routine | SEC |
| Feb 25, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 1,846 | $898k | 3.2% | Routine | SEC |
| Feb 25, 2026 | McKechnie Duncan | EVP, Chief Commercial Officer | Form 4 sale | 4,910 | $2.4M | 21.9% | Routine | SEC |
| Feb 25, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Form 4 sale | 620 | $302k | 7.8% | Routine | SEC |
| Feb 25, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 945 | $460k | 6.5% | Routine | SEC |
| Feb 25, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 668 | $325k | 3.5% | Routine | SEC |
| Feb 25, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 223 | $108k | 3.1% | Routine | SEC |
| Feb 19, 2026 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 58,613 | $27.5M | 49.9% | Unusual | SEC |
| Feb 18, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 977 | $472k | 2.0% | Routine | SEC |
| Feb 18, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Form 4 sale | 3,619 | $1.8M | 29.9% | Routine | SEC |
| Feb 18, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 3,720 | $1.8M | 19.1% | Unusual | SEC |
| Feb 18, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 2,848 | $1.4M | 12.1% | Routine | SEC |
| Feb 18, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 2,195 | $1.1M | 22.1% | Routine | SEC |
| Feb 13, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 1,500 | $750k | 3.1% | Routine | SEC |
| Feb 13, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 988 | $493k | 5.5% | Routine | SEC |
| Feb 13, 2026 | Bhatia Sangeeta N. | Director | Form 4 sale | 266 | $133k | 5.8% | Routine | SEC |
| Feb 11, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 466 | $215k | 0.9% | Routine | SEC |
| Feb 11, 2026 | Bunnage Mark E. | EVP, Chief Scientific Officer | Form 4 sale | 2,021 | $931k | 13.5% | Routine | SEC |
| Feb 11, 2026 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 1,925 | $886k | 8.5% | Routine | SEC |
| Feb 11, 2026 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 1,751 | $806k | 7.4% | Routine | SEC |
| Feb 11, 2026 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 1,376 | $634k | 12.0% | Routine | SEC |
| Jan 7, 2026 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 4,500 | $2.1M | 9.6% | Unusual | SEC |
| Jan 6, 2026 | Wagner Charles F Jr | EVP, CO & FO | Form 4 sale | 9,532 | $4.4M | 20.2% | Routine | SEC |
| Dec 3, 2025 | Wagner Charles F Jr | EVP, CO & FO | Form 4 sale | 14,000 | $6.4M | 27.1% | Unusual | SEC |
| Dec 3, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 4,500 | $2M | 8.8% | Unusual | SEC |
| Dec 3, 2025 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 63,781 | $28.7M | 72.6% | Unusual | SEC |
| Dec 3, 2025 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 347 | $156k | 2.2% | Routine | SEC |
| Nov 17, 2025 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 2,500 | $1.1M | 12.9% | Routine | SEC |
| Nov 14, 2025 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 73,292 | $32.3M | 75.3% | Unusual | SEC |
| Oct 2, 2025 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 694 | $281k | 4.2% | Routine | SEC |
| Aug 27, 2025 | Bhatia Sangeeta N. | Director | Form 4 sale | 266 | $103k | 5.5% | Routine | SEC |
| May 15, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 52 | $22k | 0.2% | Routine | SEC |
| May 2, 2025 | Bhatia Sangeeta N. | Director | Form 4 sale | 400 | $202k | 7.6% | Routine | SEC |
| Mar 13, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 3,231 | $1.6M | 12.2% | Routine | SEC |
| Mar 10, 2025 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,298 | $1.6M | 6.0% | Routine | SEC |
| Mar 10, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 3,242 | $1.6M | 6.0% | Unusual | SEC |
| Mar 10, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 3,231 | $1.6M | 10.9% | Routine | SEC |
| Mar 4, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 4,058 | $2M | 6.9% | Unusual | SEC |
| Mar 3, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 3,231 | $1.6M | 9.8% | Routine | SEC |
| Feb 27, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 530 | $252k | 0.9% | Routine | SEC |
| Feb 27, 2025 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 2,650 | $1.3M | 12.0% | Routine | SEC |
| Feb 27, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 1,272 | $611k | 3.7% | Routine | SEC |
| Feb 25, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 354 | $170k | 0.5% | Routine | SEC |
| Feb 25, 2025 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 1,767 | $850k | 6.7% | Routine | SEC |
| Feb 25, 2025 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 884 | $425k | 8.9% | Routine | SEC |
| Feb 25, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 848 | $408k | 2.1% | Routine | SEC |
| Feb 20, 2025 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 1,111 | $533k | 2.4% | Routine | SEC |
| Feb 18, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 244 | $111k | 0.4% | Routine | SEC |
| Feb 18, 2025 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 1,657 | $754k | 8.6% | Routine | SEC |
| Feb 18, 2025 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 671 | $305k | 5.9% | Routine | SEC |
| Feb 11, 2025 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 310 | $143k | 0.5% | Routine | SEC |
| Feb 11, 2025 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 3,433 | $1.6M | 17.4% | Unusual | SEC |
| Feb 11, 2025 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 1,747 | $803k | 7.0% | Routine | SEC |
| Feb 11, 2025 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 1,376 | $633k | 12.1% | Routine | SEC |
| Nov 15, 2024 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 15 | $7k | 0.1% | Routine | SEC |
| Nov 11, 2024 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,000 | $1.6M | 6.4% | Routine | SEC |
| Nov 8, 2024 | Kewalramani Reshma | CEO & President | Form 4 sale | 15,198 | $7.8M | 16.7% | Routine | SEC |
| Oct 2, 2024 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 999 | $461k | 5.7% | Routine | SEC |
| Aug 30, 2024 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 3,784 | $1.9M | 27.5% | Routine | SEC |
| Aug 30, 2024 | Bhatia Sangeeta N. | Director | Form 4 sale | 646 | $323k | 12.7% | Routine | SEC |
| Aug 8, 2024 | Bhatia Sangeeta N. | Director | Form 4 sale | 1,292 | $602k | 22.6% | Unusual | SEC |
| Aug 7, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1.1M | 8.9% | Routine | SEC |
| Aug 1, 2024 | Sachs Bruce I | Director | Form 4 sale | 5,295 | $2.7M | 11.7% | Routine | SEC |
| Jul 30, 2024 | Kewalramani Reshma | CEO & President | Form 4 sale | 15,202 | $7.7M | 14.3% | Routine | SEC |
| Jul 24, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1.1M | 8.2% | Routine | SEC |
| Jul 22, 2024 | Kewalramani Reshma | CEO & President | Form 4 sale | 15,202 | $7.6M | 12.5% | Routine | SEC |
| Jul 10, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1.1M | 7.6% | Routine | SEC |
| Jun 26, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1.1M | 7.0% | Routine | SEC |
| Jun 12, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1.1M | 6.6% | Routine | SEC |
| Jun 12, 2024 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 7,288 | $3.5M | 31.3% | Unusual | SEC |
| Jun 3, 2024 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,250 | $1.5M | 6.5% | Routine | SEC |
| Jun 3, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 2,175 | $1M | 4.2% | Unusual | SEC |
| May 31, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 4,600 | $2M | 8.2% | Unusual | SEC |
| May 29, 2024 | Bozic Carmen | EVP and CMO | Form 4 sale | 2,280 | $1M | 6.2% | Routine | SEC |
| May 28, 2024 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,250 | $1.5M | 6.1% | Routine | SEC |
| May 24, 2024 | Kewalramani Reshma | CEO & President | Form 4 sale | 1,565 | $715k | 1.3% | Routine | SEC |
| May 22, 2024 | Sachs Bruce I | Director | Form 4 sale | 7,073 | $3.2M | 15.0% | Routine | SEC |
| May 20, 2024 | Kewalramani Reshma | CEO & President | Form 4 sale | 15,202 | $6.8M | 11.1% | Routine | SEC |
| May 15, 2024 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 32 | $14k | 0.1% | Routine | SEC |
| May 15, 2024 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 69 | $30k | 0.1% | Routine | SEC |
| May 15, 2024 | Altshuler David | EVP, Chief Scientific Officer | Form 4 sale | 54 | $23k | 0.2% | Routine | SEC |
| May 2, 2024 | Bhatia Sangeeta N. | Director | Form 4 sale | 467 | $188k | 9.5% | Routine | SEC |
| Apr 2, 2024 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 240 | $101k | 3.1% | Routine | SEC |
| Feb 26, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 354 | $151k | 0.6% | Routine | SEC |
| Feb 26, 2024 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 3,004 | $1.3M | 5.2% | Routine | SEC |
| Feb 26, 2024 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 883 | $376k | 5.2% | Routine | SEC |
| Feb 26, 2024 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 5,034 | $2.1M | 9.2% | Routine | SEC |
| Feb 26, 2024 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 883 | $376k | 10.0% | Routine | SEC |
| Feb 26, 2024 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,239 | $1.8M | 14.1% | Routine | SEC |
| Feb 21, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 360 | $152k | 0.6% | Routine | SEC |
| Feb 21, 2024 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 3,191 | $1.3M | 5.0% | Routine | SEC |
| Feb 21, 2024 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 1,201 | $507k | 6.1% | Routine | SEC |
| Feb 21, 2024 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 3,603 | $1.5M | 5.7% | Routine | SEC |
| Feb 21, 2024 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 3,002 | $1.3M | 8.1% | Routine | SEC |
| Feb 20, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 480 | $202k | 0.8% | Routine | SEC |
| Feb 20, 2024 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 4,254 | $1.8M | 6.2% | Routine | SEC |
| Feb 20, 2024 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 801 | $337k | 3.9% | Routine | SEC |
| Feb 20, 2024 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 4,804 | $2M | 7.1% | Routine | SEC |
| Feb 20, 2024 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,002 | $1.7M | 9.8% | Routine | SEC |
| Feb 15, 2024 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 9,011 | $3.8M | 33.5% | Routine | SEC |
| Feb 13, 2024 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 3,393 | $1.4M | 11.2% | Routine | SEC |
| Feb 12, 2024 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 314 | $132k | 0.5% | Routine | SEC |
| Feb 12, 2024 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 3,222 | $1.4M | 4.2% | Routine | SEC |
| Feb 12, 2024 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 1,738 | $728k | 8.7% | Routine | SEC |
| Feb 12, 2024 | Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | Form 4 sale | 913 | $384k | 3.8% | Routine | SEC |
| Feb 12, 2024 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 4,295 | $1.8M | 5.4% | Routine | SEC |
| Feb 12, 2024 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 1,374 | $577k | 12.4% | Unusual | SEC |
| Feb 12, 2024 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 3,145 | $1.3M | 6.2% | Routine | SEC |
| Jan 8, 2024 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 6,648 | $2.8M | 73.3% | Routine | SEC |
| Jan 2, 2024 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,000 | $1.2M | 6.4% | Routine | SEC |
| Dec 15, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 17,135 | $7M | 13.6% | Routine | SEC |
| Dec 15, 2023 | Kewalramani Reshma | Officer, Director | Form 144 notice | 17,135 | $7M | Notice | SEC | |
| Dec 13, 2023 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 13,354 | $5.3M | 59.5% | Routine | SEC |
| Dec 13, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 5,098 | $2M | 4.5% | Routine | SEC |
| Dec 13, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 8,603 | $3.4M | 13.2% | Routine | SEC |
| Dec 13, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 13,354 | $5.3M | Notice | SEC | |
| Dec 13, 2023 | Kewalramani Reshma | Officer, Director | Form 144 notice | 5,098 | $2M | Notice | SEC | |
| Dec 13, 2023 | Arbuckle Stuart A | Officer | Form 144 notice | 8,603 | $3.4M | Notice | SEC | |
| Nov 20, 2023 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,000 | $1M | 6.0% | Routine | SEC |
| Nov 20, 2023 | Wagner Charles F Jr | Officer | Form 144 notice | 3,000 | $1M | Notice | SEC | |
| Nov 15, 2023 | Sachdev Amit | EVP Chief Patient & Ext Af Off | Form 4 sale | 35 | $13k | 0.1% | Routine | SEC |
| Nov 15, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 19 | $7k | 0.1% | Routine | SEC |
| Nov 15, 2023 | Altshuler David | Officer | Form 144 notice | 19 | $7k | Notice | SEC | |
| Nov 15, 2023 | Sachdev Amit | Officer | Form 144 notice | 35 | $13k | Notice | SEC | |
| Nov 14, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,650 | $2.2M | 16.2% | Routine | SEC |
| Nov 14, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,650 | $2.2M | Notice | SEC | |
| Nov 13, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 5,097 | $1.9M | 4.3% | Routine | SEC |
| Nov 13, 2023 | Kewalramani Reshma | Officer, Director | Form 144 notice | 5,097 | $1.9M | Notice | SEC | |
| Nov 6, 2023 | Sachs Bruce I | Director | Form 4 sale | 11,250 | $4.3M | 22.0% | Routine | SEC |
| Nov 6, 2023 | Sachs Bruce I | Director | Form 144 notice | 11,250 | $4.3M | Notice | SEC | |
| Oct 31, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,651 | $2M | 13.9% | Routine | SEC |
| Oct 31, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,651 | $2M | Notice | SEC | |
| Oct 17, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,651 | $2.1M | 12.2% | Routine | SEC |
| Oct 17, 2023 | Bhatia Sangeeta N. | Director | Form 4 sale | 243 | $91k | 5.9% | Routine | SEC |
| Oct 17, 2023 | Bhatia Sangeeta N. | Director | Form 144 notice | 243 | $91k | Notice | SEC | |
| Oct 17, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,651 | $2.1M | Notice | SEC | |
| Oct 16, 2023 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 12,962 | $4.8M | 36.6% | Routine | SEC |
| Oct 16, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 12,962 | $4.8M | Notice | SEC | |
| Oct 6, 2023 | Bhatia Sangeeta N. | Director | Form 4 sale | 242 | $87k | 5.5% | Routine | SEC |
| Oct 6, 2023 | Bhatia Sangeeta N. | Director | Form 144 notice | 242 | $87k | Notice | SEC | |
| Oct 3, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,651 | $2M | 10.9% | Routine | SEC |
| Oct 3, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,651 | $2M | Notice | SEC | |
| Oct 2, 2023 | Biller Jonathan | EVP and Chief Legal Officer | Form 4 sale | 610 | $212k | 5.5% | Routine | SEC |
| Oct 2, 2023 | Biller Jonathan | Officer | Form 144 notice | 610 | $212k | Notice | SEC | |
| Sep 19, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,651 | $2M | 9.8% | Routine | SEC |
| Sep 19, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,651 | $2M | Notice | SEC | |
| Sep 5, 2023 | Bozic Carmen | EVP and CMO | Form 4 sale | 5,651 | $2M | 8.9% | Routine | SEC |
| Sep 5, 2023 | Bozic Carmen | Officer | Form 144 notice | 5,651 | $2M | Notice | SEC | |
| Aug 23, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 2,500 | $888k | 4.9% | Unusual | SEC |
| Aug 23, 2023 | Tatsis Ourania | Officer | Form 144 notice | 2,500 | $888k | Notice | SEC | |
| Aug 10, 2023 | Kearney Terrence C | Director | Form 4 sale | 10,000 | $3.5M | 60.5% | Routine | SEC |
| Aug 10, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 5,750 | $2M | 10.1% | Unusual | SEC |
| Aug 10, 2023 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 10,031 | $3.5M | 14.6% | Routine | SEC |
| Aug 10, 2023 | Kearney Terrence C | Director | Form 144 notice | 10,000 | $3.5M | Notice | SEC | |
| Aug 10, 2023 | Sachdev Amit | Officer | Form 144 notice | 10,031 | $3.5M | Notice | SEC | |
| Aug 10, 2023 | Tatsis Ourania | Officer | Form 144 notice | 5,750 | $2M | Notice | SEC | |
| Aug 9, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 63 | $22k | 0.2% | Routine | SEC |
| Aug 9, 2023 | Bhatia Sangeeta N. | Director | Form 4 sale | 242 | $84k | 5.2% | Routine | SEC |
| Aug 9, 2023 | Bhatia Sangeeta N. | Director | Form 144 notice | 242 | $84k | Notice | SEC | |
| Aug 9, 2023 | Altshuler David | Officer | Form 144 notice | 63 | $22k | Notice | SEC | |
| Jul 17, 2023 | Sachs Bruce I | Director | Form 4 sale | 11,250 | $4M | 22.0% | Routine | SEC |
| Jul 17, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 7,828 | $2.8M | 6.2% | Routine | SEC |
| Jul 17, 2023 | Kewalramani Reshma | Officer, Director | Form 144 notice | 7,828 | $2.8M | Notice | SEC | |
| Jul 17, 2023 | Sachs Bruce I | Director | Form 144 notice | 11,250 | $4M | Notice | SEC | |
| Jun 15, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 8,603 | $3M | 13.2% | Unusual | SEC |
| Jun 15, 2023 | Arbuckle Stuart A | Officer | Form 144 notice | 8,603 | $3M | Notice | SEC | |
| May 30, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 82 | $27k | 0.1% | Routine | SEC |
| May 30, 2023 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 289 | $95k | 4.1% | Routine | SEC |
| May 30, 2023 | Arbuckle Stuart A | Officer | Form 144 notice | 82 | $27k | Notice | SEC | |
| May 8, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 3,272 | $1.1M | 9.3% | Unusual | SEC |
| May 8, 2023 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 2,004 | $700k | 5.4% | Routine | SEC |
| May 8, 2023 | Sanna Bastiano | Officer | Form 144 notice | 2,850 | $998k | Notice | SEC | |
| May 8, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 1,125 | $393k | Notice | SEC | |
| May 5, 2023 | Sanna Bastiano | Officer | Form 144 notice | 422 | $148k | Notice | SEC | |
| May 5, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 879 | $307k | Notice | SEC | |
| May 3, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 4,403 | $1.5M | 11.1% | Unusual | SEC |
| May 3, 2023 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 10,958 | $3.8M | 22.7% | Routine | SEC |
| May 3, 2023 | Sanna Bastiano | Officer | Form 144 notice | 2,781 | $975k | Notice | SEC | |
| May 3, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 4,508 | $1.6M | Notice | SEC | |
| May 2, 2023 | Bhatia Sangeeta N. | Director | Form 4 sale | 580 | $202k | 11.1% | Routine | SEC |
| May 2, 2023 | Sanna Bastiano | Officer | Form 144 notice | 1,622 | $569k | Notice | SEC | |
| May 2, 2023 | Leiden Jeffrey M | Director | Form 144 notice | 6,450 | $2.3M | Notice | SEC | |
| May 2, 2023 | Bhatia Sangeeta N. | Director | Form 144 notice | 580 | $200k | Notice | SEC | |
| Apr 27, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 3,317 | $1.1M | 2.6% | Routine | SEC |
| Apr 27, 2023 | Kewalramani Reshma | Officer, Director | Form 144 notice | 3,317 | $1.1M | Notice | SEC | |
| Apr 12, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 7,567 | $2.5M | 16.0% | Unusual | SEC |
| Apr 12, 2023 | Sachs Bruce I | Director | Form 4 sale | 21,300 | $7M | 34.1% | Routine | SEC |
| Apr 12, 2023 | Sanna Bastiano | Officer | Form 144 notice | 7,567 | $2.5M | Notice | SEC | |
| Apr 12, 2023 | Sachs Bruce I | Director | Form 144 notice | 21,300 | $7M | Notice | SEC | |
| Apr 4, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 522 | $165k | 1.1% | Routine | SEC |
| Apr 4, 2023 | Sanna Bastiano | Officer | Form 144 notice | 522 | $165k | Notice | SEC | |
| Mar 24, 2023 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 1,768 | $540k | 3.4% | Routine | SEC |
| Mar 24, 2023 | Wagner Charles F Jr | Officer | Form 144 notice | 1,768 | $540k | Notice | SEC | |
| Mar 17, 2023 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 2,000 | $593k | 3.7% | Routine | SEC |
| Mar 17, 2023 | Wagner Charles F Jr | Officer | Form 144 notice | 2,000 | $600k | Notice | SEC | |
| Mar 16, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 2,746 | $825k | 5.3% | Unusual | SEC |
| Mar 16, 2023 | Sanna Bastiano | Officer | Form 144 notice | 2,746 | $825k | Notice | SEC | |
| Mar 13, 2023 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 4,754 | $1.4M | 8.2% | Plan not stated | SEC |
| Mar 13, 2023 | Wagner Charles F Jr | Officer | Form 144 notice | 2,666 | $783k | Notice | SEC | |
| Mar 10, 2023 | Wagner Charles F Jr | Officer | Form 144 notice | 2,088 | $605k | Notice | SEC | |
| Feb 27, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 354 | $102k | 0.6% | Plan not stated | SEC |
| Feb 27, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 5,034 | $1.4M | 8.2% | Plan not stated | SEC |
| Feb 27, 2023 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 1,207 | $347k | 14.2% | Plan not stated | SEC |
| Feb 27, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,238 | $1.2M | 11.7% | Plan not stated | SEC |
| Feb 22, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 2,401 | $707k | 3.5% | Plan not stated | SEC |
| Feb 21, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 480 | $141k | 0.8% | Plan not stated | SEC |
| Feb 21, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 2,402 | $706k | 3.4% | Plan not stated | SEC |
| Feb 21, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,002 | $1.2M | 9.0% | Plan not stated | SEC |
| Feb 14, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 320 | $96k | 0.5% | Plan not stated | SEC |
| Feb 14, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 2,181 | $655k | 3.5% | Unusual | SEC |
| Feb 14, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 6,398 | $1.9M | 7.8% | Unusual | SEC |
| Feb 14, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 6,398 | $1.9M | 11.8% | Plan not stated | SEC |
| Feb 13, 2023 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 275 | $82k | 0.4% | Plan not stated | SEC |
| Feb 13, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 113 | $34k | 0.2% | Plan not stated | SEC |
| Feb 13, 2023 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 4,887 | $1.5M | 5.6% | Unusual | SEC |
| Feb 13, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,798 | $1.4M | 8.1% | Plan not stated | SEC |
| Feb 6, 2023 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,304 | $399k | 1.9% | Plan not stated | SEC |
| Jan 31, 2023 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 106 | $34k | 0.3% | Plan not stated | SEC |
| Jan 31, 2023 | Sachs Bruce I | Director | Form 4 sale | 1,200 | $390k | 2.8% | Plan not stated | SEC |
| Jan 30, 2023 | Carney Lloyd | Director | Form 4 sale | 2,700 | $865k | 39.4% | Unusual | SEC |
| Jan 27, 2023 | Lee Yuchun | Director | Form 4 sale | 1,429 | $460k | 43.3% | Unusual | SEC |
| Jan 26, 2023 | Lee Yuchun | Director | Form 4 sale | 8,000 | $2.5M | 81.0% | Unusual | SEC |
| Jan 25, 2023 | Kewalramani Reshma | CEO & President | Form 4 sale | 10,000 | $3.2M | 10.0% | Plan not stated | SEC |
| Jan 24, 2023 | Lee Yuchun | Director | Form 4 sale | 6,129 | $1.9M | 76.6% | Unusual | SEC |
| Jan 18, 2023 | Lee Yuchun | Director | Form 4 sale | 4,442 | $1.4M | 70.3% | Unusual | SEC |
| Nov 15, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 34 | $10k | 0.1% | Plan not stated | SEC |
| Nov 7, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,303 | $395k | 3.5% | Plan not stated | SEC |
| Nov 2, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 320 | $100k | 0.8% | Plan not stated | SEC |
| Oct 24, 2022 | Bhatia Sangeeta N. | Director | Form 4 sale | 621 | $193k | 13.3% | Plan not stated | SEC |
| Oct 18, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 1,791 | $538k | 4.4% | Plan not stated | SEC |
| Aug 15, 2022 | Kewalramani Reshma | CEO & President | Form 4 sale | 11,689 | $3.6M | 10.5% | Plan not stated | SEC |
| Aug 15, 2022 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 22,173 | $6.7M | 32.9% | Unusual | SEC |
| Aug 15, 2022 | Liu Joy | SVP, General Counsel | Form 4 sale | 3,747 | $1.1M | 28.1% | Unusual | SEC |
| Aug 10, 2022 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 180 | $54k | 0.3% | Plan not stated | SEC |
| Aug 10, 2022 | Liu Joy | SVP, General Counsel | Form 4 sale | 36 | $11k | 0.3% | Plan not stated | SEC |
| Aug 9, 2022 | Liu Joy | SVP, General Counsel | Form 4 sale | 946 | $284k | 6.6% | Unusual | SEC |
| Aug 9, 2022 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 1,400 | $419k | 2.9% | Unusual | SEC |
| Aug 9, 2022 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 5,690 | $1.7M | 8.5% | Unusual | SEC |
| Aug 8, 2022 | Bhatia Sangeeta N. | Director | Form 4 sale | 621 | $182k | 11.8% | Plan not stated | SEC |
| Aug 8, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,304 | $381k | 3.5% | Plan not stated | SEC |
| Jul 29, 2022 | Bhatia Sangeeta N. | Director | Form 4 sale | 621 | $173k | 10.5% | Plan not stated | SEC |
| Jul 25, 2022 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 132,079 | $37.2M | 98.2% | Unusual | SEC |
| Jul 19, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 17,865 | $5.2M | 33.1% | Unusual | SEC |
| Jun 24, 2022 | Kewalramani Reshma | CEO & President | Form 4 sale | 11,689 | $3.4M | 9.5% | Plan not stated | SEC |
| May 16, 2022 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 133 | $33k | 0.2% | Plan not stated | SEC |
| May 16, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 45 | $11k | 0.1% | Plan not stated | SEC |
| May 16, 2022 | Liu Joy | SVP, General Counsel | Form 4 sale | 133 | $34k | 0.9% | Plan not stated | SEC |
| May 4, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 36 | $10k | 0.1% | Plan not stated | SEC |
| May 2, 2022 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 306 | $81k | 0.5% | Plan not stated | SEC |
| May 2, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 320 | $83k | 0.8% | Plan not stated | SEC |
| May 2, 2022 | Bhatia Sangeeta N. | Director | Form 4 sale | 737 | $191k | 11.1% | Plan not stated | SEC |
| May 2, 2022 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 343 | $89k | 0.8% | Plan not stated | SEC |
| Apr 29, 2022 | Liu Joy | SVP, General Counsel | Form 4 sale | 120 | $33k | 0.8% | Plan not stated | SEC |
| Apr 25, 2022 | Ambrose Kristen | SVP & Chief Accounting Officer | Form 4 sale | 327 | $88k | 8.6% | Plan not stated | SEC |
| Apr 18, 2022 | Lee Yuchun | Director | Form 4 sale | 2,000 | $568k | 51.6% | Unusual | SEC |
| Apr 14, 2022 | Lee Yuchun | Director | Form 4 sale | 2,000 | $578k | 51.6% | Unusual | SEC |
| Apr 13, 2022 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 15,789 | $4.6M | 17.6% | Plan not stated | SEC |
| Apr 13, 2022 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 11, 2022 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 8, 2022 | Bhatia Sangeeta N. | Director | Form 4 sale | 1,907 | $534k | 26.9% | Unusual | SEC |
| Apr 8, 2022 | Mcglynn Margaret G | Director | Form 4 sale | 5,000 | $1.4M | 82.0% | Unusual | SEC |
| Apr 7, 2022 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 7, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 561 | $155k | 1.3% | Plan not stated | SEC |
| Apr 5, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 3,725 | $1M | 7.9% | Plan not stated | SEC |
| Apr 5, 2022 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 1, 2022 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 2,582 | $684k | 5.6% | Plan not stated | SEC |
| Mar 31, 2022 | Mcglynn Margaret G | Director | Form 4 sale | 5,000 | $1.3M | 82.0% | Unusual | SEC |
| Mar 17, 2022 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 2,833 | $709k | 5.6% | Unusual | SEC |
| Mar 17, 2022 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 3,171 | $793k | 6.4% | Plan not stated | SEC |
| Mar 17, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 2,122 | $531k | 4.2% | Plan not stated | SEC |
| Feb 25, 2022 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 325 | $75k | 0.6% | Plan not stated | SEC |
| Feb 25, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 7,572 | $1.7M | 17.3% | Unusual | SEC |
| Feb 18, 2022 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 519 | $120k | 1.0% | Plan not stated | SEC |
| Feb 18, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,312 | $996k | 8.0% | Plan not stated | SEC |
| Feb 14, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 2,444 | $567k | 4.1% | Plan not stated | SEC |
| Feb 11, 2022 | Tatsis Ourania | EVP, Chief Reg. & Quality Off. | Form 4 sale | 290 | $68k | 0.5% | Plan not stated | SEC |
| Feb 11, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 2,297 | $540k | 3.7% | Plan not stated | SEC |
| Feb 2, 2022 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 2,944 | $736k | 4.9% | Plan not stated | SEC |
| Feb 2, 2022 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 1,040 | $261k | 1.9% | Plan not stated | SEC |
| Feb 2, 2022 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 4,660 | $1.2M | 6.6% | Plan not stated | SEC |
| Jan 28, 2022 | Mcglynn Margaret G | Director | Form 4 sale | 5,000 | $1.2M | 82.0% | Unusual | SEC |
| Nov 15, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 51 | $10k | 0.2% | Plan not stated | SEC |
| Nov 15, 2021 | Arbuckle Stuart A | EVP, COO | Form 4 sale | 3 | $562 | 0.0% | Plan not stated | SEC |
| Nov 15, 2021 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 34 | $6k | 0.1% | Plan not stated | SEC |
| Jun 2, 2021 | Bhatia Sangeeta N. | Director | Form 4 sale | 559 | $117k | 9.7% | Plan not stated | SEC |
| May 17, 2021 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 112 | $24k | 0.3% | Plan not stated | SEC |
| May 17, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 45 | $10k | 0.1% | Plan not stated | SEC |
| May 17, 2021 | Liu Joy | SVP, General Counsel | Form 4 sale | 112 | $24k | 1.3% | Plan not stated | SEC |
| May 17, 2021 | Arbuckle Stuart A | EVP, Chief Comm & Ops Officer | Form 4 sale | 109 | $24k | 0.3% | Plan not stated | SEC |
| May 17, 2021 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 79 | $17k | 0.2% | Plan not stated | SEC |
| May 3, 2021 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 960 | $210k | 2.7% | Plan not stated | SEC |
| Apr 27, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 3,884 | $839k | 8.8% | Plan not stated | SEC |
| Apr 5, 2021 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 1,686 | $361k | 4.5% | Plan not stated | SEC |
| Mar 5, 2021 | Liu Joy | SVP, General Counsel | Form 4 sale | 5,141 | $1.1M | 38.4% | Unusual | SEC |
| Mar 1, 2021 | Silva Paul M | SVP & Chief Accounting Officer | Form 4 sale | 2,782 | $588k | 22.0% | Plan not stated | SEC |
| Feb 25, 2021 | Silva Paul M | SVP & Chief Accounting Officer | Form 4 sale | 1,080 | $231k | 6.8% | Plan not stated | SEC |
| Feb 25, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 3,586 | $765k | 8.2% | Plan not stated | SEC |
| Feb 25, 2021 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 3,028 | $646k | 8.9% | Plan not stated | SEC |
| Feb 25, 2021 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 3,634 | $776k | 8.1% | Plan not stated | SEC |
| Feb 25, 2021 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 3,028 | $646k | 8.3% | Plan not stated | SEC |
| Feb 18, 2021 | Silva Paul M | SVP & Chief Accounting Officer | Form 4 sale | 4,295 | $910k | 20.3% | Unusual | SEC |
| Feb 18, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 9,264 | $2M | 16.6% | Plan not stated | SEC |
| Feb 18, 2021 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 7,825 | $1.7M | 17.7% | Unusual | SEC |
| Feb 18, 2021 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 7,825 | $1.7M | 14.1% | Plan not stated | SEC |
| Feb 18, 2021 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 7,825 | $1.7M | 16.7% | Unusual | SEC |
| Feb 11, 2021 | Silva Paul M | SVP & Chief Accounting Officer | Form 4 sale | 1,498 | $315k | 5.9% | Plan not stated | SEC |
| Feb 11, 2021 | Sanna Bastiano | EVP, Cell & Genetic Therapies | Form 4 sale | 1,686 | $355k | 4.2% | Plan not stated | SEC |
| Feb 11, 2021 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 4,460 | $939k | 6.6% | Plan not stated | SEC |
| Feb 11, 2021 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 4,318 | $909k | 7.9% | Plan not stated | SEC |
| Feb 11, 2021 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 5,156 | $1.1M | 7.7% | Plan not stated | SEC |
| Feb 11, 2021 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 5,283 | $1.1M | 9.0% | Plan not stated | SEC |
| Feb 5, 2021 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 1,930 | $415k | 3.3% | Plan not stated | SEC |
| Feb 3, 2021 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 400 | $87k | 0.7% | Plan not stated | SEC |
| Feb 3, 2021 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 1,554 | $332k | 2.2% | Plan not stated | SEC |
| Nov 16, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 42 | $9k | 0.1% | Plan not stated | SEC |
| Nov 16, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 91 | $20k | 0.3% | Plan not stated | SEC |
| Nov 16, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 7 | $2k | 0.0% | Plan not stated | SEC |
| Nov 16, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 38 | $8k | 0.1% | Plan not stated | SEC |
| Nov 4, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 2,330 | $507k | 8.0% | Plan not stated | SEC |
| Nov 3, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 1,553 | $329k | 4.2% | Plan not stated | SEC |
| Oct 5, 2020 | Bhatia Sangeeta N. | Director | Form 4 sale | 10,516 | $2.8M | 72.9% | Unusual | SEC |
| Aug 6, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 1,078 | $292k | 6.7% | Plan not stated | SEC |
| Aug 6, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 1,223 | $332k | 4.4% | Plan not stated | SEC |
| Aug 6, 2020 | Kewalramani Reshma | CEO & President | Form 4 sale | 2,073 | $562k | 7.2% | Plan not stated | SEC |
| Aug 6, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,223 | $332k | 4.1% | Plan not stated | SEC |
| Aug 3, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 1,941 | $540k | 5.2% | Plan not stated | SEC |
| Aug 3, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 809 | $225k | 5.1% | Plan not stated | SEC |
| Aug 3, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 2,330 | $648k | 8.0% | Plan not stated | SEC |
| Aug 3, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 1,553 | $432k | 4.2% | Plan not stated | SEC |
| Aug 3, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 2,330 | $648k | 7.5% | Plan not stated | SEC |
| Jul 13, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 860 | $251k | 5.4% | Plan not stated | SEC |
| Jul 13, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 2,125 | $621k | 7.3% | Plan not stated | SEC |
| Jul 10, 2020 | Wagner Charles F Jr | EVP & Chief Financial Officer | Form 4 sale | 700 | $205k | 4.2% | Plan not stated | SEC |
| Jul 7, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 2,786 | $836k | 7.3% | Plan not stated | SEC |
| Jun 30, 2020 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 32,792 | $9.4M | 93.5% | Unusual | SEC |
| Jun 2, 2020 | Bhatia Sangeeta N. | Director | Form 4 sale | 952 | $269k | 14.3% | Plan not stated | SEC |
| May 15, 2020 | Kewalramani Reshma | CEO & President | Form 4 sale | 99 | $28k | 0.4% | Plan not stated | SEC |
| May 15, 2020 | Tatsis Ourania | EVP, Chief Regulatory Officer | Form 4 sale | 120 | $34k | 0.9% | Plan not stated | SEC |
| May 15, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 151 | $43k | 1.0% | Plan not stated | SEC |
| May 15, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 58 | $16k | 0.2% | Plan not stated | SEC |
| May 15, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 68 | $19k | 0.3% | Plan not stated | SEC |
| May 15, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 113 | $32k | 0.3% | Plan not stated | SEC |
| May 15, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 82 | $23k | 0.3% | Plan not stated | SEC |
| May 12, 2020 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 94,370 | $26.8M | 73.0% | Unusual | SEC |
| May 12, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,304 | $375k | 4.3% | Plan not stated | SEC |
| May 11, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 10,665 | $3M | 23.3% | Plan not stated | SEC |
| May 11, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 1,304 | $373k | 4.6% | Plan not stated | SEC |
| May 7, 2020 | Sachs Bruce I | Director | Form 4 sale | 45,000 | $12.1M | 80.1% | Unusual | SEC |
| May 7, 2020 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 94,369 | $25.5M | 69.8% | Unusual | SEC |
| May 6, 2020 | Tatsis Ourania | EVP, Chief Regulatory Officer | Form 4 sale | 966 | $263k | 7.0% | Plan not stated | SEC |
| May 6, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 1,076 | $293k | 6.7% | Plan not stated | SEC |
| May 6, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 669 | $184k | 1.9% | Plan not stated | SEC |
| May 6, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 1,222 | $333k | 4.4% | Plan not stated | SEC |
| May 6, 2020 | Kewalramani Reshma | CEO & President | Form 4 sale | 2,074 | $566k | 7.2% | Plan not stated | SEC |
| May 6, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 1,222 | $333k | 4.1% | Plan not stated | SEC |
| May 5, 2020 | Leiden Jeffrey M | Executive Chairman | Form 4 sale | 94,372 | $25.5M | 66.9% | Unusual | SEC |
| May 5, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 57,108 | $15.1M | 61.9% | Unusual | SEC |
| May 4, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 1,553 | $405k | 4.2% | Plan not stated | SEC |
| May 4, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 809 | $211k | 5.1% | Plan not stated | SEC |
| May 4, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 2,330 | $608k | 8.0% | Plan not stated | SEC |
| May 4, 2020 | Altshuler David | EVP, Global Research and CSO | Form 4 sale | 2,330 | $608k | 7.5% | Plan not stated | SEC |
| Apr 29, 2020 | Parini Michael | EVP, Chief Adm, Leg & BD Off | Form 4 sale | 2,125 | $542k | 7.3% | Plan not stated | SEC |
| Apr 28, 2020 | Lee Yuchun | Director | Form 4 sale | 1,125 | $290k | 37.5% | Unusual | SEC |
| Apr 27, 2020 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 23, 2020 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 21, 2020 | Lee Yuchun | Director | Form 4 sale | 4,000 | $1.1M | 68.1% | Unusual | SEC |
| Apr 13, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 859 | $214k | 5.4% | Plan not stated | SEC |
| Apr 6, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 4,891 | $1.2M | 24.7% | Unusual | SEC |
| Feb 25, 2020 | Tatsis Ourania | SVP, CRO | Form 4 sale | 1,296 | $302k | 9.2% | Plan not stated | SEC |
| Feb 25, 2020 | Silva Paul M | SVP & Controller | Form 4 sale | 1,080 | $252k | 6.7% | Plan not stated | SEC |
| Feb 25, 2020 | Sachdev Amit | EVP, Chief Patient Officer | Form 4 sale | 3,376 | $788k | 9.3% | Plan not stated | SEC |
| Feb 25, 2020 | Parini Michael | EVP, CL&AO | Form 4 sale | 3,028 | $707k | 10.1% | Plan not stated | SEC |
| Feb 25, 2020 | Leiden Jeffrey M | CEO & President | Form 4 sale | 10,550 | $2.5M | 10.2% | Plan not stated | SEC |
| Feb 25, 2020 | Kewalramani Reshma | EVP and CMO | Form 4 sale | 3,634 | $848k | 12.0% | Plan not stated | SEC |
| Feb 25, 2020 | Arbuckle Stuart A | EVP, Chief Commercial Officer | Form 4 sale | 3,634 | $849k | 9.4% | Plan not stated | SEC |